Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890695879> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- W2890695879 endingPage "6606" @default.
- W2890695879 startingPage "6606" @default.
- W2890695879 abstract "6606 Background: Current value frameworks (VFs) assess clinical value primarily through using clinical trial endpoints as survival metrics (e.g., median and hazard ratio (HR)). But, if key assumptions do not hold, the interpretation of these summary statistics can become problematic and fail to adequately capture the expected benefit to a patient. This has been observed with innovative oncology treatments. As a proof of concept analysis, we reviewed how two VFs (ASCO and ESMO) dealt with cases where the assumption of proportional hazards (PH) does not hold. Methods: Oncology agents approved by the FDA since 2011 were reviewed and three agents were identified with survival profiles where the assumption of PH was found not to hold because, on visual inspection, the survival curves displayed non-standard patterns: Divergence followed by convergence – panobinostat OS in RRMM; Curves initially track together then diverge – nivolumab OS in NSCLC; Curves diverge steadily then a plateau emerged in the active treatment curve – pembrolizumab PFS in refractory melanoma. We evaluated these agents to assess which measures of clinical benefit were most valued under each VF and how the issue of non-PH influenced the outcome. Results: Clinical benefit/value scores varied: ASCO: 14-27 (maximum 100), ESMO: grade 1-3. The ASCO VF uses a hierarchical approach (incorporating HR and median survival benefit, always prioritising the former) adding a bonus for survival benefit in the tail of the distribution. The combination of HR, median survival benefit 2 and 3 year survival rates in the ESMO non-curative VF can potentially capture aspects of clinical benefit in some cases of non-PH. Overall, the ASCO VF appears less flexible to accommodate non-PH than the ESMO VF. Conclusions: Despite VFs using summary statistics which cannot be easily interpreted under conditions of non-PH, the case of non-PH is not explicitly catered for. Additionally, both VFs may miss important interpretation where value is differentiated across patients groups with different response profiles which may underlie non-standard survival curves. In these situations, a more flexible approach to assessing clinical value may render VFs more relevant for clinical decision making." @default.
- W2890695879 created "2018-09-27" @default.
- W2890695879 creator A5041710083 @default.
- W2890695879 creator A5048873376 @default.
- W2890695879 creator A5077759824 @default.
- W2890695879 creator A5082165315 @default.
- W2890695879 date "2017-05-20" @default.
- W2890695879 modified "2023-09-27" @default.
- W2890695879 title "Can we satisfactorily measure the clinical value of new oncology agents with a single summary measure?" @default.
- W2890695879 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.6606" @default.
- W2890695879 hasPublicationYear "2017" @default.
- W2890695879 type Work @default.
- W2890695879 sameAs 2890695879 @default.
- W2890695879 citedByCount "0" @default.
- W2890695879 crossrefType "journal-article" @default.
- W2890695879 hasAuthorship W2890695879A5041710083 @default.
- W2890695879 hasAuthorship W2890695879A5048873376 @default.
- W2890695879 hasAuthorship W2890695879A5077759824 @default.
- W2890695879 hasAuthorship W2890695879A5082165315 @default.
- W2890695879 hasConcept C10515644 @default.
- W2890695879 hasConcept C121608353 @default.
- W2890695879 hasConcept C126322002 @default.
- W2890695879 hasConcept C143998085 @default.
- W2890695879 hasConcept C207103383 @default.
- W2890695879 hasConcept C2776598537 @default.
- W2890695879 hasConcept C2777701055 @default.
- W2890695879 hasConcept C2780030458 @default.
- W2890695879 hasConcept C2780057760 @default.
- W2890695879 hasConcept C44249647 @default.
- W2890695879 hasConcept C71924100 @default.
- W2890695879 hasConceptScore W2890695879C10515644 @default.
- W2890695879 hasConceptScore W2890695879C121608353 @default.
- W2890695879 hasConceptScore W2890695879C126322002 @default.
- W2890695879 hasConceptScore W2890695879C143998085 @default.
- W2890695879 hasConceptScore W2890695879C207103383 @default.
- W2890695879 hasConceptScore W2890695879C2776598537 @default.
- W2890695879 hasConceptScore W2890695879C2777701055 @default.
- W2890695879 hasConceptScore W2890695879C2780030458 @default.
- W2890695879 hasConceptScore W2890695879C2780057760 @default.
- W2890695879 hasConceptScore W2890695879C44249647 @default.
- W2890695879 hasConceptScore W2890695879C71924100 @default.
- W2890695879 hasIssue "15_suppl" @default.
- W2890695879 hasLocation W28906958791 @default.
- W2890695879 hasOpenAccess W2890695879 @default.
- W2890695879 hasPrimaryLocation W28906958791 @default.
- W2890695879 hasRelatedWork W2155654588 @default.
- W2890695879 hasRelatedWork W2296139876 @default.
- W2890695879 hasRelatedWork W2415283090 @default.
- W2890695879 hasRelatedWork W2557996697 @default.
- W2890695879 hasRelatedWork W2809118688 @default.
- W2890695879 hasRelatedWork W2811288290 @default.
- W2890695879 hasRelatedWork W2911229154 @default.
- W2890695879 hasRelatedWork W2957427793 @default.
- W2890695879 hasRelatedWork W3181948680 @default.
- W2890695879 hasRelatedWork W3185931698 @default.
- W2890695879 hasVolume "35" @default.
- W2890695879 isParatext "false" @default.
- W2890695879 isRetracted "false" @default.
- W2890695879 magId "2890695879" @default.
- W2890695879 workType "article" @default.